AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37420013
Drug: Falls and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Falls and treatment for dizziness
Trial: 37420013
Drug: Dizziness treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dizziness treatment
Trial: 37420268
Drug: Digital therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital therapy (Playball)
Trial: 37420268
Drug: Non-digital therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-digital therapy
Trial: 37420274
Drug: PF-06804103 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06804103 3.0 mg/kg Q3W
Trial: 37420274
Drug: PF-06804103 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06804103 4.0 mg/kg Q3W
Trial: 37420274
Drug: PF-06804103 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06804103 (all doses)
Trial: 37421291
Drug: TEER with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEER with MitraClip plus guideline-directed medical therapy (GDMT)
Trial: 37421320
Drug: In-laboratory titration
RxNorm normalized name: A & L Laboratories Protect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-laboratory titration polysomnography (tPSG)
Trial: 37421604
Drug: Crovalimab (C5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crovalimab (C5 inhibitor), loading doses (one intravenous, four subcutaneous) and subsequent every-4-weeks subcutaneous maintenance doses per weight-based tiered-dosing schedule.
Trial: 37421604
Drug: Crovalimab (C5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crovalimab (C5 inhibitor)
Trial: 37422079
Drug: Rilematovir 500
RxNorm normalized name: Rilematovir
DrugBank: Rilematovir (DB15672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilematovir 500 mg
Trial: 37422079
Drug: Rilematovir 80
RxNorm normalized name: Rilematovir
DrugBank: Rilematovir (DB15672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilematovir 80 mg
Trial: 37422241
Drug: 3-L polyethylene
RxNorm normalized name: 3-(L-MENTHOXY)-2-METHYLPROPANE-1,2-DIOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-L polyethylene glycol (PEG)
Trial: 37422518
Drug: SCTV01E (30 µg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCTV01E (30 µg)
Trial: 37422518
Drug: SCTV01C (20 µg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCTV01C (20 µg)
Trial: 37422518
Drug: BNT162b2 (20 µg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 (20 µg)
Trial: 37422666
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous unfractionated heparin (UFH) therapy
Trial: 37422666
Drug: Subcutaneous low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous low-molecular-weight heparin (LMWH) injection
Trial: 37422688
Drug: Azacitidine 75
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine 75 mg/m², venetoclax, and pevonedistat
Trial: 37422772
Drug: BAY1128688 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY1128688 3 mg once daily
Trial: 37422772
Drug: BAY1128688 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY1128688 10 mg once daily
Trial: 37422772
Drug: BAY1128688 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY1128688 30 mg once daily
Trial: 37422772
Drug: BAY1128688 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY1128688 30 mg twice daily
Trial: 37422772
Drug: BAY1128688 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY1128688 60 mg twice daily
Trial: 37423228
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg IV every 3 weeks)
Trial: 37423228
Drug: Single-agent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent chemotherapy (vinorelbine or gemcitabine, dosing per local label)
Trial: 37423231
Drug: Baricitinib (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib (4 mg once daily)
Trial: 37423623
Drug: CAB+RPV long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAB+RPV long-acting (LA) administration
Trial: 37423647
Drug: Active conventional
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active conventional therapy
Trial: 37423717
Drug: Mepolizumab 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab 300 mg monthly for 3 months
Trial: 37423717
Drug: Mepolizumab 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab 300 mg monthly for 6 months (mepo/mepo)
Trial: 37423717
Drug: Placebo followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by Mepolizumab 100 mg monthly for 3 months (pbo/mepo)
Trial: 37423801
Drug: H-SC (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H-SC (600 mg fixed-dose)
Trial: 37423834
Drug: Fosaprepitant 150
RxNorm normalized name: fosaprepitant 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosaprepitant 150 mg i.v. dissolved in 0.9% saline 150 ml
Trial: 37423834
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% saline 150 ml)
Trial: 37424311
Drug: Legume group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Legume group (20% TPI, 200 g RPM per week)
Trial: 37424311
Drug: Meat group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meat group (25% TPI, 760 g RPM per week)
Trial: 37424700
Drug: DLBS3233 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DLBS3233 (100 mg once per day)
Trial: 37424700
Drug: Metformin XR
RxNorm normalized name: metformin Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin XR (750 mg twice per day)
Trial: 37424700
Drug: DLBS3233 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DLBS3233 (100 mg once per day) + Metformin XR (750 mg twice per day)
Trial: 37425298
Drug: TTV load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTV load and QF-Mg
Trial: 37426086
Drug: Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) treatment
Trial: 37426430
Drug: Mesenchymal stromal
RxNorm normalized name: Mesenchymal Stromal Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stromal cells (MSC) infusion at 6 and 7 weeks post-transplantation
Trial: 37426430
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no MSC infusion)
Trial: 37427566
Drug: Repeated SI
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated SI (transplant to the duodenum twice)
Trial: 37428030
Drug: Intervention to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention to reduce cardiovascular risk; details on dosage and duration not available.
Trial: 37428347
Drug: Palbociclib plus
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib plus Aromatase Inhibitor (AI)
Trial: 37428347
Drug: Aromatase Inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase Inhibitor (AI) monotherapy
Trial: 37428480
Drug: Abatacept (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept (10 mg/kg; maximum dose, 1000 mg)
Trial: 37428480
Drug: Cenicriviroc (300-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenicriviroc (300-mg loading dose followed by 150 mg twice per day)
Trial: 37428504
Drug: Deprescribing intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deprescribing intervention (physician-pharmacist collaborative drug therapy management, standard-of-care practice recommendations, shared decision-making, and deprescribing protocols administered by telephone for a maximum of 180 days)
Trial: 37428681
Drug: Post-opioid administration
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-opioid administration
Trial: 37428866
Drug: Supplemental ready-to-use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental ready-to-use therapeutic food (RUTF) with moderate-dose hydroxyurea therapy (20 mg/kg per day)
Trial: 37428866
Drug: Supplemental ready-to-use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental ready-to-use therapeutic food (RUTF) without moderate-dose hydroxyurea therapy
Trial: 37429122
Drug: Vagus Nerve
RxNorm normalized name: SUS SCROFA VAGUS NERVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vagus Nerve Stimulation (VNS) titration according to Group A protocol
Trial: 37429122
Drug: Vagus Nerve
RxNorm normalized name: SUS SCROFA VAGUS NERVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vagus Nerve Stimulation (VNS) titration according to other protocols (Group B and Group C)
Trial: 37429122
Drug: Vagus Nerve
RxNorm normalized name: SUS SCROFA VAGUS NERVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vagus Nerve Stimulation (VNS) titration (all groups)
Trial: 37429302
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg intravenously on day 1 of every 21-day cycle for a maximum of 24 months
Trial: 37429622
Drug: 0.15% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% ropivacaine injected, 1 mL at a time, up to 1.0 mL.kg
Trial: 37429622
Drug: Local anesthetics
RxNorm normalized name: LOCAL ANESTHETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetics of 0.223, 0.591, and 0.797 mL.kg
Trial: 37429637
Drug: C reactive
RxNorm normalized name: C reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C reactive protein >3 mg/L
Trial: 37429637
Drug: Left atrial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left atrial volume index >34 mL/m²
Trial: 37429687
Drug: Ciclosporin (CsA)
RxNorm normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ciclosporin (CsA) as first-line treatment for atopic dermatitis.
Trial: 37429687
Drug: Ciclosporin (CsA)
RxNorm normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ciclosporin (CsA) therapy (for patients already receiving or who have received CsA).
Trial: 37429923
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg every 3 weeks) + lenvatinib (20 mg daily)
Trial: 37429923
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg every 3 weeks) + anti-CTLA-4 quavonlimab (25 mg every 6 weeks)
Trial: 37429923
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg every 3 weeks) + anti-LAG-3 favezelimab (200 mg or 800 mg every 3 weeks)
Trial: 37430077
Drug: Oral zeaxanthin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zeaxanthin (Zx) 20 mg daily for ≥ 5 years
Trial: 37430233
Drug: Usual dose
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual dose lipid emulsion
Trial: 37430233
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose lipid emulsion (half of the usual dose)
Trial: 37430359
Drug: Intraoperative goal-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative goal-directed fluid therapy (GDFT)
Trial: 37430359
Drug: Restrictive fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive fluid therapy (RFT)
Trial: 37430375
Drug: High daily
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High daily urinary output (> 436 ml/d)
Trial: 37431406
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy for Health in Adolescents (AHEAD)
Trial: 37432025
Drug: Single-dose recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) at 50 L
Trial: 37432025
Drug: Single-dose recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) at 800 L
Trial: 37432025
Drug: Single-dose recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) at 50 L in Scale B
Trial: 37432025
Drug: Single-dose recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) at 500 L
Trial: 37432311
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) for ≥2 years
Trial: 37432430
Drug: Cytisinicline, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytisinicline, 3 mg, 3 times daily for 6 weeks
Trial: 37432430
Drug: Cytisinicline, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytisinicline, 3 mg, 3 times daily for 12 weeks
Trial: 37432430
Drug: Placebo, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 3 times daily for 6 weeks
Trial: 37432430
Drug: Placebo, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 3 times daily for 12 weeks
Trial: 37432723
Drug: CBT-txt (SMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-txt (SMS text message-delivered cognitive behavioral therapy)
Trial: 37432736
Drug: ATG plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG plus granulocyte colony-stimulating factor (ATG/G-CSF)
Trial: 37433021
Drug: Combination regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination regimens of Ad26.RSV.preF and RSV preF protein
Trial: 37433021
Drug: Combination regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination regimen comprising Ad26.RSV.preF and RSV preF protein
Trial: 37433173
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg/FA 0.4 mg tablet daily (A group)
Trial: 37433173
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg/FA 0.8 mg tablet daily (B group)
Trial: 37433173
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg daily (C group, control group)
Trial: 37433729
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) administered at a rate of 0.1 µg/kg/hour for 48 hours during general anaesthesia induction.
Trial: 37433729
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) administered at the same rate as DEX in the control group.
Trial: 37433734
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of bupivacaine
Trial: 37434165
Drug: High-dose acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose acupuncture (HA, 7 times each chemo-cycle for 3 cycles)
Trial: 37434165
Drug: Low-dose acupuncture
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acupuncture (LA, 3 times each chemo-cycle for 3 cycles)
Trial: 37434165
Drug: High-dose acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose acupuncture (HA)
Trial: 37434165
Drug: Low-dose acupuncture
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acupuncture (LA)
Trial: 37434306
Drug: Adjuvant endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant endocrine therapy (ET)
Trial: 37434306
Drug: Early discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early discontinuation model
Trial: 37435073
Drug: Bivalent norovirus
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant
Trial: 37435299
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (medication reconciliation or MedRec) without MedSafer reports
Trial: 37435777
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral anticoagulation (no OAC)
Trial: 37436730
Drug: Any mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any mental health disorder/psychotropic prescription
Trial: 37436730
Drug: Socioeconomic difficulties
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Socioeconomic difficulties associated with mental health disorder/psychotropic prescriptions
Trial: 37436797
Drug: Antipneumococcal antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipneumococcal antibody titers
Trial: 37437144
Drug: BRAF-MEK inhibitor
RxNorm normalized name: Mitogen-activated protein kinase (MEK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRAF-MEK inhibitor combination vemurafenib-cobimetinib
Trial: 37437575
Drug: Intensive and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive and personalized-dosage cumulative intervention combining brain-computer interface, exoskeleton, multi-channel functional electrical stimulation, and anodal transcranial direct current stimulation
Trial: 37437608
Drug: High-dose intensity-modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intensity-modulated radiotherapy (RT) with pre-operative helical tomotherapy, delivering 54 Gy/30 fractions
Trial: 37437694
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (antihypertensive medications with goal blood pressure <140/90 mm Hg)
Trial: 37437694
Drug: Control (deferred
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (deferred treatment until blood pressure ≥160/105 mm Hg)
Trial: 37437885
Drug: Vilaprisan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan (2 mg/d)
Trial: 37438197
Drug: ivacaftor therapy
RxNorm normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ivacaftor therapy
Trial: 37438493
Drug: Oral prolonged-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prolonged-release tablet (1.9 mg melatonin)
Trial: 37438493
Drug: Immediate-release sublingual
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release sublingual spray (1 mg melatonin)
Trial: 37438759
Drug: Swallowing and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swallowing and oral-care (SOC) program; average of 6.2 days of intervention (14.8 min daily).
Trial: 37438759
Drug: Swallowing and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swallowing and oral-care (SOC) program; adjusted hazard ratio 2.35; 95% CI 1.38-4.01.
Trial: 37438759
Drug: Swallowing and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swallowing and oral-care (SOC) program; adjusted odds ratio 0.28; 95% CI 0.12-0.65.
Trial: 37438776
Drug: Nudge intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nudge intervention comprising three SMS text message reminders with links to short educational videos and vaccine safety information.
Trial: 37439084
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with radiotherapy (n=18)
Trial: 37439084
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy without radiotherapy (n=5)
Trial: 37439219
Drug: Half-dose tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half-dose tenecteplase followed by coronary angiography and PCI (if indicated)
Trial: 37439219
Drug: Half-dose tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half-dose tenecteplase and Primary PCI
Trial: 37439343
Drug: Tenalisib 800
RxNorm normalized name: Tenalisib
DrugBank: Tenalisib (DB15295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenalisib 800 mg twice daily orally and romidepsin 14 mg/m2 intravenous on days 1, 8, and 15 in 28-day cycles
Trial: 37439373
Drug: Metabolite levels
RxNorm normalized name: Terfenadine acid metabolite
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metabolite levels (S1P, L-arginine, kynurenine, acyl-carnitines, bile acids)